Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Bristol Myers Squibb (NYSE:BMY) today announced that it has priced a public offering (the "Offering") of senior unsecur...
BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost...
Cleveland-Cliffs shares gained 1.4% to close at $12.43 on Friday while Bristol-Myers Squibb shares gained 1% to close at $46.07.
Multiple real-world analyses and an analysis of long-term extension data reinforce the well-established efficacy and safety pro...
Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol Myers Squibb" or the "Offeror"), announced the commencement o...
Bristol Myers beats Q3 forecasts with $12.22 billion revenue and a higher 2025 sales outlook, driven by strong demand for Reblo...
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...
